These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 17722855)

  • 1. Even for a minimalist, EPO has clear value.
    Reynolds J
    Nephrol News Issues; 2007 Aug; 21(9):47, 49. PubMed ID: 17722855
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic kidney disease, anemia, and epoetin.
    Roger SD
    N Engl J Med; 2007 Mar; 356(9):958; author reply 958-9. PubMed ID: 17338047
    [No Abstract]   [Full Text] [Related]  

  • 3. EPO use: let the patients be involved in the decision.
    Peters KK
    Nephrol News Issues; 2007 Aug; 21(9):49-50. PubMed ID: 17722856
    [No Abstract]   [Full Text] [Related]  

  • 4. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
    Bradbury BD; Do TP; Winkelmayer WC; Critchlow CW; Brookhart MA
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dialysis facility ownership and epoetin dosing in hemodialysis patients: an overview.
    Weiner DE; Levey AS
    Am J Kidney Dis; 2007 Sep; 50(3):349-53. PubMed ID: 17720511
    [No Abstract]   [Full Text] [Related]  

  • 6. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a dialysis provider's perspective.
    Lazarus JM; Hakim RM
    Am J Kidney Dis; 2007 Sep; 50(3):366-70. PubMed ID: 17720515
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
    Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
    Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a view from Europe.
    Macdougall IC
    Am J Kidney Dis; 2007 Sep; 50(3):358-61. PubMed ID: 17720513
    [No Abstract]   [Full Text] [Related]  

  • 9. Dialysis facility ownership and epoetin dosing in hemodialysis patients: a medical economic perspective.
    Cohen JT; Neumann PJ
    Am J Kidney Dis; 2007 Sep; 50(3):362-5. PubMed ID: 17720514
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
    Locatelli F; Villa G; Messa P; Filippini A; Cannella G; De Ferrari G; Naso A; Rossi E; Formica M; Lombardi L; Rotolo U; Conte F
    J Nephrol; 2008; 21(3):412-20. PubMed ID: 18587731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients.
    Chan KE; Lafayette RA; Whittemore AS; Hlatky MA; Moran J
    Nephrol Dial Transplant; 2008 Sep; 23(9):2948-56. PubMed ID: 18469314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it time to reconsider subcutaneous administration of epoetin?
    Patel TV; Robinson K; Singh AK
    Nephrol News Issues; 2007 Oct; 21(11):57, 59, 63-4 passim. PubMed ID: 17970510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory trend analyses and proactive adjustments to minimize the need for holding epoetin alfa doses.
    Breiterman-White R; Reznicek J
    Nephrol Nurs J; 2008; 35(6):577-81, 600. PubMed ID: 19260609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of age on hemoglobin levels and quality of life following treatment with epoetin alfa in cancer patients.
    Puglisi F; Deroma L; Russo S; Cartenì G; Sporchia A; Ucci G; De Signoribus G; Del Prete S; Vecchione A; Pinotti G; Beccaglia P
    Crit Rev Oncol Hematol; 2009 Feb; 69(2):175-82. PubMed ID: 18774730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
    Walker RG
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring relative mortality and epoetin alfa dose among hemodialysis patients.
    Bradbury BD; Wang O; Critchlow CW; Rothman KJ; Heagerty P; Keen M; Acquavella JF
    Am J Kidney Dis; 2008 Jan; 51(1):62-70. PubMed ID: 18155534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent assessment of longitudinal laboratory trends: a key to minimizing hemoglobin variability in patients on dialysis.
    Brooks D
    Nephrol Nurs J; 2007; 34(4):435-9. PubMed ID: 17891912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin alfa in the critically ill: What dose? Which route?
    Napolitano LM
    Crit Care Med; 2009 Apr; 37(4):1501-3. PubMed ID: 19318838
    [No Abstract]   [Full Text] [Related]  

  • 20. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms.
    Glaspy JA; Charu V; Luo D; Moyo V; Kamin M; Wilhelm FE
    Cancer; 2009 Mar; 115(5):1121-31. PubMed ID: 19170225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.